Karuna Therapeutics shares rose 2.4% this afternoon to a price of $329.73. The stock is still trading within range of its average target price of $322.67, and over the last 52 weeks, it has recorded a 70.1% performance. Analysts have given the Large-Cap Pharmaceutical stock target prices ranging from $260.0 to $330.0 dollars per share, with an average rating of hold.
Karuna Therapeutics has an average level of shares sold short, at 6.0% of its total share float. The stock's short ratio (also called days to cover) is 3.6. The company's insiders own 4.99% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 86.4% of Karuna Therapeutics's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Karuna Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-12-31 | Capital International Investors | 11% | 4,227,102 | $1,393,802,388 |
| 2023-12-31 | Vanguard Group Inc | 8% | 3,224,786 | $1,063,308,723 |
| 2023-12-31 | FMR, LLC | 8% | 2,865,994 | $945,004,233 |
| 2023-12-31 | T. Rowe Price Investment Management, Inc. | 7% | 2,709,629 | $893,445,999 |
| 2023-12-31 | Blackrock Inc. | 5% | 2,015,374 | $664,529,291 |
| 2023-12-31 | Price (T.Rowe) Associates Inc | 5% | 1,961,587 | $646,794,103 |
| 2023-12-31 | Sofinnova Investments, Inc. | 4% | 1,381,149 | $455,406,274 |
| 2023-12-31 | Wellington Management Group, LLP | 3% | 1,134,046 | $373,929,000 |
| 2023-12-31 | Pentwater Capital Management Lp | 3% | 1,066,200 | $351,558,137 |
| 2023-12-31 | General Atlantic, L.P. | 3% | 986,710 | $325,347,899 |
